Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00 at JPMorgan Chase & Co.

Amicus Therapeutics (NASDAQ:FOLD) had its price objective lifted by JPMorgan Chase & Co. from $16.00 to $17.00 in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Morgan Stanley dropped their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Cantor Fitzgerald boosted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Finally, Bank of America boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded down $0.27 during trading hours on Tuesday, reaching $9.82. 683,554 shares of the company’s stock were exchanged, compared to its average volume of 2,719,125. The stock’s 50 day moving average is $11.04 and its 200-day moving average is $10.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,398,532.40. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 30,401 shares of company stock valued at $352,038. 2.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Janus Henderson Group PLC raised its position in shares of Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after acquiring an additional 2,307,385 shares during the period. William Blair Investment Management LLC raised its position in shares of Amicus Therapeutics by 12.8% in the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after acquiring an additional 1,477,084 shares during the period. Fiera Capital Corp raised its position in shares of Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after acquiring an additional 58,113 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Amicus Therapeutics by 4.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock worth $33,749,000 after acquiring an additional 139,491 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Amicus Therapeutics by 10.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after acquiring an additional 242,672 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.